Get the Stockscreener App
17.58
19.24%
-4.09
Cullinan Therapeutics Inc stock is traded at $17.58, with a volume of 1.51M.
It is down -19.24% in the last 24 hours and down -19.28% over the past month.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
See More
Previous Close:
$21.67
Open:
$21.67
24h Volume:
1.51M
Relative Volume:
1.81
Market Cap:
$1.12B
Revenue:
-
Net Income/Loss:
$-221.04M
P/E Ratio:
-4.7331
EPS:
-3.7143
Net Cash Flow:
$-178.65M
1W Performance:
-15.17%
1M Performance:
-19.28%
6M Performance:
+36.29%
1Y Performance:
+187.36%
1-Day Range:
$16.97
$21.67
1-Week Range:
$16.97
$21.88
52-Week Range:
$5.68
$23.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
17.41 | 1.39B | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
512.78 | 130.53B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.15 | 82.77B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
183.32 | 72.88B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
938.28 | 60.30B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
363.87 | 41.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | Citigroup | Buy |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance UK
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - The Manila Times
Cullinan Therapeutics - The Pharma Letter
Phase III results could broaden opportunity for Cullinan’s lead cancer drug - The Pharma Letter
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Potential Upside of Over 57% Ignites Investor Interest - DirectorsTalk Interviews
Should Phase 3 Lung Cancer Data Require Action From Cullinan Therapeutics (CGEM) Investors? - simplywall.st
Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity? - finance.yahoo.com
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $42 - Moomoo
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $42 - Moomoo
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst CallSlideshow (NASDAQ:CGEM) 2026-09-14 - Seeking Alpha
Cullinan Oncology stock rating reaffirmed at Buy by TD Cowen - Investing.com South Africa
BTIG raises Cullinan Oncology stock price target on trial data - Investing.com
BTIG raises Cullinan Oncology stock price target on trial data By Investing.com - Investing.com Canada
Cullinan Therapeutics: The Market Shrugged At REZILIENT3, But Catalysts Await (CGEM) - Seeking Alpha
Stifel reiterates Cullinan Oncology stock Buy rating on trial data By Investing.com - Investing.com South Africa
Stifel reiterates Cullinan Oncology stock Buy rating on trial data - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results - Yahoo Finance
CGEM: Zipalertinib plus chemotherapy achieved unprecedented PFS and CNS efficacy in first-line EGFR exon 20 NSCLC - TradingView
CGEM: Zipalertinib plus chemotherapy significantly improved PFS and ORR in EGFR ex20ins NSCLC - TradingView
Cullinan Therapeutics: Zipalertinib + chemo cuts median PFS to 14.5 vs 8.5 months in REZILIENT3 - TradingView
Cullinan Therapeutics to Host Virtual Investor Event on Phase 3 REZILIENT3 Zipalertinib Data from IASLC WCLC 2026 - Quiver Quantitative
Cullinan Therapeutics to Host Virtual Analyst and Investor - GlobeNewswire
Squarepoint Ops LLC Invests $3.06 Million in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $40.00 at BTIG Research - MarketBeat
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - Investing News Network
Cullinan Therapeutics (CGEM) Advances Lung Cancer Trial; Valuati - GuruFocus
Zipalertinib plus chemo shows survival benefit in lung cancer trial By Investing.com - Investing.com UK
Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
EGFR-NSCLC Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innova - Barchart.com
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Investing News Network
Cullinan Therapeutics to Present Phase 3 REZILIENT3 Interim Data on Zipalertinib Plus Chemotherapy at WCLC 2026, Host Investor Event - Quiver Quantitative
Cullinan Therapeutics CSO Jennifer Michaelson Executes 8,000 Share Sale Under 10b5-1 Plan - Kalkine Media
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (CGEM) insider sells 8,000 shares under pre-arranged plan - Stock Titan
171,031 Shares in Cullinan Therapeutics, Inc. $CGEM Bought by Bank of New York Mellon Corp - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Corient Private Wealth LP Takes $970,000 Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
The Manufacturers Life Insurance Company Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded to Hold at Wall Street Zen - MarketBeat
CGEM Stock Price, Quote & Chart - ChartMill
Moore Capital Management LP Raises Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Algert Global LLC Sells 72,880 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
BlackRock Inc. Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - marketbeat.com
Connor Clark & Lunn Investment Management Ltd. Takes Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Elmind Capital LP Purchases New Shares in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Boone Capital Management LLC Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cullinan Therapeutics Inc Stock (CGEM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer |
Sep 08 '26 |
Sale |
21.57 |
8,000 |
172,560 |
158,844 |
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):